. 2015 Aug 31;7:463–476. doi: 10.2147/CEOR.S87462

Table S1.

List of all submissions that were accepted with ICERs higher than the threshold, by HTA agency

Drug	Indication	BNF Category	Manufacturer’s base-case ICER	Nature of acceptance	Key rationale provided by HTA body^a
Drug	Indication	BNF Category	Manufacturer’s base-case ICER	Nature of acceptance	PAS/risk sharing scheme^b	Unmet need/lack of alternative therapeutic options	High clinical benefit^c	Orphan/rare disease	End of life considerations
NICE (£)
Abiraterone + prednisolone	Castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen	Malignant disease and immunosuppression	52,851	Accepted	X				X
Adalimumab	Plaque psoriasis	Skin	30,500	Restricted
Azacitidine	Myelodysplasic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia	Malignant disease and immunosuppression	47,432	Accepted	X		X		X
Bortezomib	Multiple myeloma	Malignant disease and immunosuppression	38,000	Accepted	X	X	X
Certolizumab	Rheumatoid arthritis	Musculoskeletal and joint diseases	34,930	Restricted	X
Fingolimod	Highly active relapsing-remitting multiple sclerosis	Malignant disease and immunosuppression	55,634	Accepted	X		X
Gefitinib	Locally advanced or metastatic non-small-cell lung cancer	Malignant disease and immunosuppression	35,992	Accepted	X
Golimumab +methotrexate	Rheumatoid arthritis	Musculoskeletal and joint diseases	31,464	Restricted	X
Ipilimumab	Previously treated advanced (unresectable or metastatic) melanoma	Malignant disease and immunosuppression	60,737	Accepted	X				X
Mannitol dry powder	Cystic fibrosis	Respiratory system	47,095	Restricted		X	X
Mifamurtide	High-grade resectable nonmetastatic osteosarcoma in children, adolescents and young adults	Malignant disease and immunosuppression	56,683	Accepted	X	X	X
Natalizumab	Multiple sclerosis	Malignant disease and immunosuppression	44,600	Restricted		X
Pazopanib	Metastatic renal cell carcinoma	Malignant disease and immunosuppression	32,898	Accepted	X		X		X
Pemetrexed	Non-small-cell lung cancer (maintenance)	Malignant disease and immunosuppression	33,065	Accepted			X		X
Pemetrexed + cisplatin	Locally advanced or metastatic non-small-cell lung cancer	Malignant disease and immunosuppression	33,732	Accepted			X
Pirfenidone	Idiopathic pulmonary fibrosis	Musculoskeletal and joint diseases	36,327	Restricted	X
Ranibizumab	Visual impairment due to diabetic macular edema	Eye	30,277	Restricted	X		X
Sunitinib	Unresectable and/or metastatic malignant gastrointestinal stromal tumors	Malignant disease and immunosuppression	47,628	Accepted	X				X
Trabectedin	Advanced soft tissue sarcoma	Malignant disease and immunosuppression	56,985	Accepted	X				X
Trastuzumab + cisplatin and capecitabine or 5-FU	Gastric cancer (HER2-positive, metastatic)	Malignant disease and immunosuppression	51,927	Restricted					X
Ustekinumab	Plaque psoriasis	Skin	30,664	Accepted	X
Vemurafenib	Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma	Malignant disease and immunosuppression	56,410	Accepted	X	X	X		X
SMC (£)
Axitinib	Advanced renal cell carcinoma	Malignant disease and immunosuppression	33,837	Accepted	X	X	X
Carglumic acid	Hyperammonaemia	Nutrition and blood	81,000	Restricted		X	X	X
Crizotinib	Previously treated ALK-positive advanced non-small-cell lung cancer	Malignant disease and immunosuppression	42,295	Accepted	X	X	X
Dasatinib	Leukemia	Malignant disease and immunosuppression	44,456	Restricted			X
Dimethyl fumarate	Relapsing-remitting multiple sclerosis	Malignant disease and immunosuppression	73,724	Accepted	X	X	X
Elvitegravir + cobicistat + emtricitabine + tenofovir disoproxil (as fumarate)	Treatment-naïve HIV	Infections	1,332,746	Accepted	X
Infliximab	Ulcerative colitis in children and adolescents	Musculoskeletal and joint diseases	35,000	Restricted		X	X
Lenalidomide	Transfusion-dependent anemia	Malignant disease and immunosuppression	57,930	Accepted		X	X	X
Mecasermin	Severe primary insulin-like growth factor-l deficiency	Endocrine System	47,729	Accepted		X	X	X
Methylnaltrexone bromide	Opioid-induced constipation	Gastrointestinal system	32,284	Restricted			X
Nelarabine	T-cell acute lymphoblastic leukemia/lymphoma	Malignant disease and immunosuppression	56,107	Restricted			X	X
Parathyroid hormone	Severe osteoporosis in postmenopausal women	Endocrine System	107,000	Restricted			X
Pazopanib	Advanced renal cell carcinoma	Malignant disease and immunosuppression	62,414	Accepted	X
Pemetrexed	Malignant pleural mesothelioma	Malignant disease and immunosuppression	35,600	Restricted		X	X
Plerixafor	Lymphoma and multiple myeloma	Nutrition and blood	39,649	Accepted			X	X
Tacrolimus	Prophylaxis of transplant rejection in heart allograft recipients	Malignant disease and immunosuppression	35,000	Restricted
Ustekinumab	Plaque psoriasis	Skin	97,063	Restricted	X
Vemurafenib	BRAF V600 mutation-positive unresectable or metastatic melanoma	Malignant disease and immunosuppression	39,617	Restricted	X	X	X
CADTH (CAN$)
Erlotinib	Non-small-cell lung cancer	Malignant disease and immunosuppression	71,000	Restricted			X
Tipranavir	HIV infection	Infections	52,000	Restricted			X
Sunitinib	Gastrointestinal stromal tumor	Malignant disease and immunosuppression	80,000	Restricted			X
Deferasirox	Iron overload	Nutrition and blood	67,595	Restricted		X
Rufinamide	Lennox-Gastaut syndrome; adjunctive treatment of seizures	Central nervous system	55,715	Restricted		X	X
Asenapine	Bipolar I disorder	Central nervous system	72,623	Restricted		X
Tocilizumab	Juvenile idiopathic arthritis	Musculoskeletal and joint diseases	69,845	Restricted			X
PBAC(AUS$)
Afatinib	Locally advanced or metastatic non-small-cell lung cancer in patients with EGFR gene mutation(s)	Malignant disease and immunosuppression	45,000–75,000	Accepted	X
Bevacizumab	Metastatic colorectal cancer	Malignant disease and immunosuppression	45,000–75,000	Accepted	X		X
Carmustine	Malignant glioma	Malignant disease and immunosuppression	105,000–200,000	Restricted	X
Dabrafenib	BRAF V600 mutation positive melanoma	Malignant disease and immunosuppression	45,000–75,000	Accepted	X	X	X
Erlotinib	Locally advanced or metastatic non-squamous non-small-cell lung cancer in patients with evidence of activating EGFR mutation(s)	Malignant disease and immunosuppression	45,000–75,000	Accepted	X		X
Everolimus	Postmenopausal women with hormone-receptor positive, HER2 negative advanced breast cancer after failure of letrozole or anastrozole	Malignant disease and immunosuppression	45,000–75,000	Accepted	X
Everolimus	Subependymal giant cell astrocytoma	Malignant disease and immunosuppression	45,000–75,000	Accepted	X	X	X
Infliximab	Severe plaque psoriasis	Skin	45,000–75,000	Restricted			X
Pazopanib	Advanced (unresectable and/or metastatic) soft tissue sarcoma	Malignant disease and immunosuppression	45,000–75,000	Accepted		X
Raltegravir	HIV infection in antiretroviral experienced patients	Infections	45,000–75,000	Accepted			X
Somatropin	Prader-Willi Syndrome	Endocrine System	45,000–75,000	Accepted			X
Sunitinib	Malignant pancreatic neuroendocrine tumor	Malignant disease and immunosuppression	45,000–75,000	Accepted	X	X		X
Sunitinib malate	Gastrointestinal stromal tumor	Malignant disease and immunosuppression	45,000–75,000	Accepted	X	X
Sunitinib malate	Advanced/metastatic renal cell carcinoma	Malignant disease and immunosuppression	45,000–75,000	Accepted	X	X
Tamsulosin hydrochloride	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Obstetrics, gynecology, and urinary tract disorders	45,000–75,000	Restricted	X
Verteporfin	Subfoveal choroidal neovascularisation	Eye	45,000–75,000	Accepted			X

Notes:

Reflects information available in the publically available summary document only. Additional criteria not stated in this document may also have contributed to acceptance;

includes discounts, patient-access schemes, price capping agreements, and outcomes-linked schemes;

covers improved efficacy improved safety, and/or improved patient quality of life.

Abbreviations: ICERs, incremental cost-effectiveness ratios; HTA, health technology assessment; BNF, British National Formulary; PAS, patient access scheme; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium; CADTH, Canadian Agency for Drugs and Technologies in Health; PBAC, Pharmaceutical Benefits Advisory Committee.